HONG KONG, Apr 24, 2025 - (ACN Newswire via SeaPRwire.com) – HighTide Therapeutics, Inc. (2511.HK), a clinical stage biopharmaceutical company specializing in the development of multifunctional multi-targeted therapies for chronic liver and metabolic diseases, announced today that it will present at the EASL Congress 2025, taking place from May 7-10, 2025 in Amsterdam. The presentations include post-hoc analyses of two Phase 2 clinical studies of berberine ursodeoxycholate (HTD1801), a gut-liver anti-inflammatory metabolic modulator, being developed for treatment of metabolic dysfunction-associated steatohepatitis (MASH) and type 2 diabetes mellitus (T2DM). A third presentation will present preclinical results for rimtoregtide (HTD4010), a peptide derived from the Reg3a protein, in liver failure in mice.“Effects of Berberine Ursodeoxycholate (HTD1801) in Patients with At-risk MASH and T2DM”(Presentation SAT-440, Poster Presentation, May 10, 8:30 AM CET)About the Abstract: Due to the ongoing unmet medical need, clinical development in MASH focuses on patients who are at a higher risk of disease progression and outcomes due to the presence of moderate to advanced fibrosis (defined as at-risk MASH). The purpose of this analysis was to assess the effects of HTD1801 in patients with at-risk MASH and T2DM as defined by baseline MRI cT1 >875 ms. Eighteen weeks of treatment with HTD1801 resulted in substantial improvements in key hepatic and cardiometabolic parameters in patients with at-risk MASH and compared to placebo, twice as many patients achieved a reduction in liver fat content (MRI-PDFF) or fibroinflammation (cT1) that have been associated with improvements in liver histology. These data are particularly insightful as HTD1801 continues to be evaluated in an ongoing paired biopsy study of patients with at-risk MASH and pre-diabetes or diabetes.“Effects of Berberine Ursodeoxycholate (HTD1801) in Chinese Patients with T2DM and Presumed MASLD”(Presentation SAT-432, Poster Presentation, May 10, 8:30 AM CET)About the Abstract: T2DM typically coexists with other metabolic abnormalities such as hyperlipidemia, obesity, and MASH that can exacerbate T2DM and can lead to a worse prognosis with increased risk for mortality and cardiovascular outcomes. In a Phase 2 study in patients with T2DM, HTD1801 achieved the primary endpoint with a significant decrease in HbA1c. Based on the latest diagnostic criteria, it is likely that a substantial subgroup of the study may have had concurrent metabolic dysfunction-associated steatotic liver disease (MASLD). The purpose of this analysis was to evaluate the benefits of HTD1801 in patients with T2DM and MASLD identified by baseline controlled attenuation parameter values >288 dB/M (correlated to 5% liver fat content). HTD1801 treatment demonstrated both dose-dependent improvements in cardiometabolic and hepatic parameters in patients with T2DM and MASLD. These data suggest HTD1801 can comprehensively address metabolic and cardiovascular risk factors beyond glycemic control.“A Comparison of the Protective Effects of Rimtoregtide (HTD4010) and DUR-928 on Acute Liver Failure in Mice”(Presentation FRI-141, Poster Presentation, May 9, 8:30 AM CET)About the Abstract: The purpose of this study was 1) to test the potential protective effects of HTD4010 in an LPS-induced model mimicking acute liver failure in mice and 2) compare these effects to DUR-928, which is currently in late-stage development for the treatment of alcohol-associated hepatitis. In an LPS-induced mouse model mimicking acute liver failure, HTD4010 resulted in significant improvement in survival rates (greater than 2-fold) compared to the model control.  These protective effects of HTD4010 were significantly greater than DUR-928.  These findings provide evidence that HTD4010 may have a beneficial effect on acute liver conditions including alcohol-associated hepatitis and other acute-inflammatory-related conditions.About Berberine UrsodeoxycholateBerberine ursodeoxycholate (HTD1801) is an orally delivered, gut-liver anti-inflammatory metabolic modulator being developed for the treatment of metabolic and digestive diseases. HTD1801, an ionic salt of berberine and ursodeoxycholate, is a new molecular entity with a unique dual mechanism of action: AMP kinase activation and NLRP3 inflammasome inhibition. These two key mechanistic pathways have been associated with improvements in insulin resistance, glucose metabolism, lipid metabolism, and hepatic inflammation, potentially providing a comprehensive treatment platform for the multifaceted nature of complex metabolic diseases. HTD1801 is being developed for multiple indications. HTD1801 met the primary endpoint in two Phase 3 clinical trials in patients with type 2 diabetes mellitus (T2DM), demonstrating a clinically meaningful effect on HbA1c. In both trials, key secondary endpoints were achieved, suggesting multiple advantages of HTD1801 including improvement in cardiometabolic risk indicators. In addition to T2DM, HTD1801 efficacy in treating metabolic dysfunction-associated steatohepatitis (MASH) has been demonstrated in a Phase 2a clinical trial, and a global multicenter Phase 2b trial assessing the histologic benefit of HTD1801 is currently ongoing, with topline results expected in 2025.About RimtoregtideRimtoregtide (HTD4010) is a clinical-stage compound in development for acute inflammatory-related indications including alcoholic hepatitis (AH). It is a peptide derived from the Reg3a protein with immunomodulatory, anti-inflammatory, and anti-apoptotic effects. HTD4010 has been evaluated in animal models of acute pancreatitis and acute liver failure, where protective effects were observed. A completed Phase 1 clinical trial of HTD4010 in healthy subjects demonstrated a favorable safety profile. AH is caused by chronic heavy alcohol abuse or a sudden, drastic increase in alcohol consumption. It is characterized by severe inflammation and, ultimately, liver failure and death. There is currently no approved treatment for AH and only a few drug candidates are in clinical development. The current standard of care focuses on symptom management, including abstinence, treating inflammation and providing nutrition.About HighTide TherapeuticsHighTide Therapeutics, Inc. (Stock Code: 2511.HK) is a globally integrated biopharmaceutical company focusing on the discovery and development of first-in-class multifunctional, multi-targeted therapies with poly-indication potential across metabolic diseases with significant unmet medical needs. HighTide is currently developing several clinical assets and associated global intellectual property rights, and advancing multiple mid-to-late-stage clinical trials including therapies for metabolic dysfunction-associated steatohepatitis (MASH), type 2 diabetes mellitus (T2DM), severe hypertriglyceridemia (SHTG) and primary sclerosing cholangitis (PSC). Berberine ursodeoxycholate (HTD1801), HighTide’s lead drug candidate, received Fast Track designation from the United States Food and Drug Administration for both MASH and PSC and Orphan Drug designation for PSC. HTD1801 has been included in the National Major New Drug Innovation Program under the 13th Five-Year Plan for Major Technology Project in China.For more information, please visit www.hightidetx.comContact: pr@hightidetx.com Copyright 2025 ACN Newswire via SeaPRwire.com.

JAKARTA, Apr 24, 2025 - (ACN Newswire via SeaPRwire.com) - South East Asia’s first premium service airline, PT TransNusa Aviation Mandiri, is further strengthening its presence in Singapore by increasing the frequency of its scheduled flights for the Jakarta – Singapore route to two times daily from today.This announcement comes barely a month after TransNusa successfully launch scheduled flights to Perth from its base in Bali.TransNusa Group Chief Executive Officer, Datuk Bernard Francis said that TransNusa has plans to further strengthen its network connectivity this year.In line with this, TransNusa launched its second daily flight to Singapore today. The additional flight, 8B 153, departed at 12.10pm from the Terminal 3 Soekarno – Hatta International Airport and arrived Singapore Changi Airport at 14.40pm today. While its additional flight, 8B 154, departed Changi Airport at 15.30pm and arrived at the Soekarno – Hatta International Airport at 16.20pm.“TransNusa will continue to operate the current scheduled flight, 8B 151, which depart Soekarno – Hatta International Airport at 07.55am and arrive at 10.45am at the Changi Airport,” Datuk Bernard said, adding that the current flight, 8B 152, depart Changi Airport at 11.45am and arrive in Jakarta at 12.30pm.TransNusa has been consistently achieving milestones since the introduction of a new top management led by aviation veteran, Datuk Bernard Francis. The airline, which introduced its first international flight on April 14, 2023, has expanding its wings from South East Asia to the Asia Pacific region within a short span of 2 years.Datuk Bernard attributes the airline’s successes and accelerated growth within the last 24 months to their customised business model and the vastly experienced management team.Datuk Bernard stressed that for its international flights, TransNusa not only provide premium services with competitive ticket prices, but the airline also has attractive product bundles called SEAT, SEAT-PLUS and FLEXI-PRO."Our passengers will enjoy check-in baggage of between 20kgs to 30 kgs, depending on the product purchased,” Datuk Bernard said, explaining that the baggage offering was over and above the 7kgs limit offered as a passenger’s hand carry.“For the highest package, FLEXI-PRO, we provide more complete services such as free baggage 30kgs, free to choose seats, free food, and drinks, priority at check-in and boarding. In addition, TransNusa also provides its FLEXI-PRO passengers with the ability to be able to change their flight schedule without restrictions and obtain refund when needed.”TransNusa, which aims to ensure its passengers travel with ease and comfort, has also configured their A320s with a 174-seat configuration, which allows for passengers to enjoy about 30 inches of legroom, comparable to the experience passengers would get in a full-service airline."We are committed to providing affordable and competitive ticket prices, while still providing premium services to our customers.” said Datuk Bernard, adding that the ticket price for the Jakarta – Singapore route starts from as low as SGD52 (USD40).DATUK BERNARD FRANCIS… TransNusa to focus on strengthening network connectivityTransNusa, A Short HistoryTransNusa, which had to close it business operation in September 2020 due to impact of the Covid-19 pandemic on the aviation industry, started operations again after injection of new shareholders and a new management team led by aviation expert, Datuk Bernard, in October 2022.Within 6 months, the airline introduced its first international route between Jakarta and Kuala Lumpur and celebrated its first-year anniversary for this route on April 14, 2024.“When we re-launched TransNusa in October 2022, we started from the bottom again. Everything was new because the pandemic had disrupted the aviation business operations boundaries. As such we re-created and customised our business operations and strategy model of being the first Premium Service Carrier based on the post-pandemic scenario,” Datuk Bernard explained.TransNusa launched its first international route between Jakarta and Kuala Lumpur in April, 2023, followed by the Jakarta – Singapore route on November 20, 2023. After which, the airline successfully launched three more new international routes by the end of 2023. TransNusa’s aggressive international growth strategy combined with its domestic business operations approach has enabled the airline to experience strategic growth in the last two years.Since the takeover of new shareholders and the injection of a new management team, TransNusa has been making headlines in Malaysia, Singapore, China and Australia with news of being the first airline in Indonesia and the world to develop and introduce a new domestic route connecting Bali and Manado. TransNusa also became the second Indonesian airline to receive approval to fly to China.About TransNusaEstablished in 2005, TransNusa started its operation by providing chartered flights. It began its commercial flights in 2011. After ceasing operations due to the Covid-19 pandemic, TransNusa relaunched itself in 2021 as a low-cost airline in its domestic market. In 2023, TransNusa introduced a new business model making it the first Premium Service Airline in the region. The new business model will apply only to its international routes. TransNusa introduced its first international route in April this year. The airline introduced its Jakarta – Kuala Lumpur round trip route and had its maiden flight on April 14. The airline is currently based in Jakarta Soekarno-Hatta International Airport.Passengers can book their flights on the TransNusa website (www.transnusa.co.id), through authorized travel agents in Singapore and Indonesia, or by contacting the airline's customer service centre at, +62216310888. For the Singaporean market, passengers can contact TransNusa’s General Sales Agent, Chariot Travels Pte Ltd, at +65 86602719.Media ContactTrina Thomas Rajtrina@myqaseh.org+60124992672 (watsapp) Copyright 2025 ACN Newswire via SeaPRwire.com.

- Results from the first patient cohort (N=5) of an open-label proof of concept academic study with low-dose IL-2 and CTLA4-Ig demonstrated a rapid and durable statistically significant increase in the number and suppressive function of Tregs compared to baseline values. - Clinically, patients with Frontotemporal Dementia (FTD) demonstrated minimal to no cognitive decline throughout the study period. Treatment was well tolerated, no serious adverse events were reported, and all 5 patients completed the study.Houston, TX, Apr 24, 2025 - (ACN Newswire via SeaPRwire.com) - Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function announced positive interim results of an investigator-initiated proof of concept open-label study with low-dose IL-2 and CTLA4-Ig combination treatment in patients with Frontotemporal Dementia (FTD). The study is led by Dr. Alireza Faridar and Dr. Stanley Appel at the Houston Methodist Neurological Institute (Houston, TX) with funding from The Peggy and Gary Edwards Endowment Fund. Study patients received subcutaneously administered CTLA4-Ig, followed by a 5-day course of low-dose IL-2 every four weeks, for a total of 22 weeks of dosing and follow-up. The study aims to enroll up to 10 patients, and these interim results include data from the first 5 patients with mild to moderate FTD who have completed the full course of treatment.Dr. Arun Swaminathan, Coya’s Chief Executive Officer followed: “The results thus far are consistent with previously published encouraging data from an open-label investigator-initiated study of patients with ALS treated with low-dose IL-2/CTLA4-Ig.  This interim data in FTD provides us further confidence of our approach to target and enhance Treg biology to address devastating neurodegenerative diseases including ALS and FTD”.Previous biomarker data presented by the Company demonstrated that FTD patients exhibit a compromised immunosuppressive function of regulatory T cells (Tregs), along with increased peripheral levels of inflammatory cytokines and chemokines, dysregulation of monocytes, and systemic activation of the inflammatory cascade, supporting the critical role of the immune system in the pathophysiology of FTD.One previous study showed that a cohort of 68 patients with FTD worsened by an average of 3.57 points over a 12-month period per the Clinical Dementia Rating - Frontotemporal Lobar Degeneration (CDR‐FTLD) scale (Knopman et al. Brain 2008; 131(11): 2957-2968). In addition, patients with FTD typically have shorter survival times and more rapid rates of cognitive and functional decline compared to patients with Alzheimer’s disease (Rascovsky et al. Neurology 2005; 65(3): 397-403).Dr. Fred Grossman, Coya’s Chief Medical Officer stated: “We are excited with the results observed in this initial group of patients with this proof-of-concept study.  We believe that the increase in Treg numbers and suppressive function, with subsequent anti-inflammatory biological activity still to be evaluated, underscores the potential for this low-dose IL-2/CTLA4-Ig combination to be further studied as a therapy for FTD, for which there are no currently approved treatments.”Summary of Interim Study Results      Overall, treatment with low-dose IL-2 and CTLA4-Ig was well tolerated.  All 5 patients enrolled in the first cohort completed the study and received the investigational treatment as planned.  The most common adverse events were mild injection site reactions. No serious adverse events were reported.Treg numbers and suppressive function increased after the first treatment cycle (p < 0.01 and p < 0.05, respectively, and remained at higher significant levels throughout the treatment period.Clinical functional assessments were performed in all patients at pre-specified timepoints over the course of the study using validated tools, including the Clinical Dementia Rating - Frontotemporal Lobar Degeneration (CDR‐FTLD) scale, the Montreal Cognitive Assessment (MoCA) scale, and the Progressive Aphasia Severity Scale (PASS).  Results of the functional tests show that, on average, these five FTD patients treated with low-dose IL-2 and CTLA4-Ig combination exhibited minimal to no cognitive decline over the course of the study, compared to pre-treatment values.The Company intends to publish and/or present more comprehensive data in a future peer-reviewed meeting and/or publication.About Frontotemporal DementiaFrontotemporal dementia (FTD) refers to a group of neurodegenerative disorders characterized by altered behavior and language, with a progressive decline in executive function.1 FTD affects an estimated 30,000 Americans.2 FTD is categorized clinically into various subtypes; the main three include behavioral-variant frontotemporal dementia and two language variants, semantic dementia (also known as semantic variant primary progressive aphasia) and progressive non-fluent aphasia (also known as non-fluent variant primary progressive aphasia).  It's a presenile dementia, meaning it can occur in younger individuals, often between the ages of 45 and 64. The average age of onset is 58, with an average survival time of 7.5 years.1,2References1. Knopman et al. Development of methodology for conducting clinical trials in frontotemporal lobar degeneration. Brain 2008; 131(11): 2957-29682. Rascovsky et al. Rate of progression differs in frontotemporal dementia and Alzheimer disease. Neurology 2005; 65(3): 397-403About Coya Therapeutics, Inc.Headquartered in Houston, TX, Coya Therapeutics, Inc. (Nasdaq: COYA) is a clinical-stage biotechnology company developing proprietary treatments focused on the biology and potential therapeutic advantages of regulatory T cells (“Tregs”) to target systemic inflammation and neuroinflammation. Dysfunctional Tregs underlie numerous conditions, including neurodegenerative, metabolic, and autoimmune diseases, and this cellular dysfunction may lead to sustained inflammation and oxidative stress resulting in lack of homeostasis of the immune system.Coya’s investigational product candidate pipeline leverages multiple therapeutic modalities aimed at restoring the anti-inflammatory and immunomodulatory functions of Tregs. Coya’s therapeutic platforms include Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.COYA 302 is a combination treatment comprised of low-dose IL-2 and CTLA4-Ig is an investigational therapy with a dual immunomodulatory mechanism of action intended to enhance the anti-inflammatory function of Tregs and suppress the inflammation produced by activated monocytes and macrophages. Coya is developing COYA 302 for the treatment of fatal neurogenerative diseases characterized by chronic inflammation and Treg dysfunction.For more information about Coya, please visit www.coyatherapeutics.com Forward-Looking StatementsThis press release contains “forward-looking” statements that are based on our management’s beliefs and assumptions and on information currently available to management. Forward-looking statements include all statements other than statements of historical fact contained in this presentation, including information concerning our current and future financial performance, business plans and objectives, current and future clinical and preclinical development activities, timing and success of our ongoing and planned clinical trials and related data, the timing of announcements, updates and results of our clinical trials and related data, our ability to obtain and maintain regulatory approval, the potential therapeutic benefits and economic value of our product candidates, competitive position, industry environment and potential market opportunities. The words “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” and similar expressions are intended to identify forward-looking statements.Forward-looking statements are subject to known and unknown risks, uncertainties, assumptions and other factors including, but not limited to, those related to risks associated with the success, cost and timing of our product candidate development activities and ongoing and planned clinical trials; our plans to develop and commercialize targeted therapeutics; the progress of patient enrollment and dosing in our preclinical or clinical trials; the ability of our product candidates to achieve applicable endpoints in the clinical trials; the safety profile of our product candidates; the potential for data from our clinical trials to support a marketing application, as well as the timing of these events; our ability to obtain funding for our operations; development and commercialization of our product candidates; the timing of and our ability to obtain and maintain regulatory approvals; the rate and degree of market acceptance and clinical utility of our product candidates; the size and growth potential of the markets for our product candidates, and our ability to serve those markets; our commercialization, marketing and manufacturing capabilities and strategy; future agreements with third parties in connection with the commercialization of our product candidates; our expectations regarding our ability to obtain and maintain intellectual property protection; our dependence on third party manufacturers; the success of competing therapies or products that are or may become available; our ability to attract and retain key scientific or management personnel; our ability to identify additional product candidates with significant commercial potential consistent with our commercial objectives; ; and our estimates regarding expenses, future revenue, capital requirements and needs for additional financing.We have based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, business strategy, short-term and long-term business operations and objectives, and financial needs. Moreover, we operate in a very competitive and rapidly changing environment, and new risks may emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed herein may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Although our management believes that the expectations reflected in our forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances described in the forward-looking statements will be achieved or occur. We undertake no obligation to publicly update any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.Investor Contact:David Snyder, CFOdavid@coyatherapeutics.com CORE IRBret Shapirobrets@coreir.com 561-479-8566Media ContactsFor Coya Therapeutics:Kati Waldenburgmedia@coyatherapeutics.com212-655-0924 Copyright 2025 ACN Newswire via SeaPRwire.com.

SINGAPORE, Apr 25, 2025 - (ACN Newswire via SeaPRwire.com) - The Board of Directors (“Board”) of Mooreast Holdings Ltd. (“Mooreast” or the “Company”), and together with its subsidiaries, the “Group”) wishes to provide an update on several recent developments: Completion of Multi-Buoy Mooring Upgrade Project at Gulf of ThailandFurther to the Company’s announcement dated 12 November 2024, Mooreast wishes to update that the project to upgrade a multi-buoy mooring (“MBM”) system off the eastern shore of the Gulf of Thailand was completed recently. The Group expects to recognise approximately S$8.8 million for this project in the first half of the financial year ending 31 December 2025 (“1H2025”).The successful completion underscores the Group’s capabilities to handle sizeable mooring projects within the oil and gas (“O&G”) industry. Orders related to the O&G sector had been building up in 2H2024, and have continued to gain momentum in the first four months of FY2025. Even with the delivery of the MBM project, current orders at hand are at least equal to those at the end of FY2024. Accordingly, the Group expects revenue in 1H2025 to exceed the S$13.7 million recorded in 1H2024.       Additionally, the Group does not expect that the administrative and other operating expenses to increase significantly in FY2025 given that the current staffing is sufficient to support operations and business development in the near term and the absence of fees for professional services rendered to support the Group’s business repositioning efforts in FY2024. Management is actively reviewing and implementing cost control measures to improve overall cost efficiency and profitability moving forward.Update on Floating Wind Energy Projects in Europe and North AsiaOn 1 January 2025, Mr. Eirik Ellingsen (“Mr. Ellingsen”), a Norwegian with deep experience in the offshore and marine sector, was appointed Chief Executive Officer (“CEO”). In the last four months, he has been working closely with Mr. Sim Koon Lam (“Mr Sim”), the founder, Executive Director and Deputy Chairman, on business development strategies amid an increase in commercialisation of floating wind energy projects worldwide.Mr. Ellingsen has been actively engaging players involved in floating wind energy projects in Europe and North Asia, and participated in the WindEurope conference in Copenhagen, Denmark, earlier this month. While the ‘first wave’ of implementation – involving largely demonstration and precommercial projects – had been delayed by the supply chain disruptions caused by the COVID-19 pandemic, the industry has clearly advanced to the ‘second wave’ – commercialisation at scale. With the progress toward commercialisation, the Environmental Resources Management’s “Q3 2024 Global Offshore Wind Market Update" reported over 390 GW of floating wind projects in various planning and development stages. Compared to 50-100 megawatts (“MW”) typical at pre-commercialisation, the latter involves projects of at least 500 MW each. Many of these projects are reaching the final investment decision (“FID”) phase in 2026 and 2027. These include multigigawatt (“GW”) scale projects which can contribute substantially to the growth of offshore wind capacity globally. Typically, mooring and rigging solutions, including anchors, chains, and ropes, account for between 5% to 10% of the total value of each floating wind energy project.           Approximately 5.5 GW of floating wind capacity is expected to reach FID in the next 24-36 months. Of this, about two-thirds involve projects in Europe, including those in the North Sea, while a third will come from North Asia. These projects may be deemed as the addressable market of Mooreast. As the Group is currently not targeting U.S. floating wind energy projects, it is not subject to U.S. Government tariffs for its products. Already, Mooreast is working closely with these projects and has indicated its component costings. As these progress to full implementation, developers and partners are looking for a reliable manufacturer capable of handling the large volumes of anchors and mooring components required for these large-scale projects. The Group believes it is uniquely positioned, given its status as Asia’s only ultra-high power anchor designer and manufacturer and its global footprint. Mooreast recently opened new offices in Taiwan and Malaysia in June and July 2024, respectively, expanding its presence in the Asian region.The Group continues to assess the ability of its present facility at 51 Shipyard Road in Singapore to handle production of anchors and components as these projects advance to formal tender, noting that developers have indicated suppliers would need to demonstrate beforehand sufficient capacity to handle the indicative volume. Should such orders escalate beyond the current capacity of the existing yard, Mooreast would need to explore access to additional capacity. Meanwhile, the Company continues to develop its supply chain to better serve its customers globally. The Company will provide updates to shareholders as and when there are material developments regarding floating renewable energy projects. BY ORDER OF THE BOARD MOOREAST HOLDINGS LTD.Mr Eirik Ellingsen Chief Executive Officer23 April 2025This announcement has been reviewed by the Company’s sponsor, UOB Kay Hian Private Limited (the “Sponsor”). This announcement has not been examined or approved by the Singapore Exchange Securities Trading Limited (“SGX-ST”) and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.  The contact person for the Sponsor is Mr Lance Tan, Senior Vice President, 8 Anthony Road, #01-01, Singapore 229957, telephone (65) 6590 6881. Copyright 2025 ACN Newswire via SeaPRwire.com.

香港, 2025年4月24日 - (亚太商讯 via SeaPRwire.com) - 君圣泰医药（股票代码: 2511.HK），一家专注于开发多功能创新疗法以解决代谢性疾病未满足临床需求的医药公司，今日宣布将于欧洲肝脏研究协会（EASL）2025年大会（5月7日-10日，荷兰阿姆斯特丹）上发表三项研究成果，分别为熊去氧胆小檗碱（HTD1801，一种全球首创的靶向肠-肝系统的抗炎及代谢调节剂）针对代谢相关脂肪性肝炎（MASH）治疗的临床2期研究事后分析结果、针对2型糖尿病（T2DM）治疗的临床2期研究事后分析结果，以及Rimtoregtide（HTD4010，一种Reg3α衍生肽）在肝衰竭小鼠中的临床前研究结果。"熊去氧胆小檗碱（HTD1801）在处于进展风险的MASH合并T2DM 患者中的疗效"（摘要SAT-440，欧洲中部时间5月10日，8:30AM，墙报）摘要：伴有中度至重度肝纤维化的MASH患者面临较高的疾病进展与不良结局风险，当下对于这类患者的诊疗存在明确的未满足临床需求，因此MASH领域的临床研究聚焦于该人群。本次分析旨在评估在患有较高进展风险MASH（定义为基线MRI cT1 >875 ms）且合并T2DM的患者中HTD1801的疗效。结果显示，经过HTD1801治疗18周后，患者在多项关键肝脏及心脏代谢指标上均有显著改善。HTD1801治疗组中，肝脂含量（MRI-PDFF）或纤维性炎症指标（cT1）达到和肝组织学改善相关的下降水平的患者数是安慰剂组的两倍。HTD1801目前正在全球开展一项基于肝脏活检的临床2b期研究，受试者为患有较高进展风险MASH 合并T2DM或糖尿病前期的患者。本研究分析结果对于HTD1801的后续开发具有重要意义。"熊去氧胆小檗碱（HTD1801）在中国T2DM合并疑似MASLD患者中的研究结果"（摘要SAT-432，欧洲中部时间5月10日，8:30AM，墙报）摘要：T2DM常伴有高脂血症、肥胖、MASH等代谢异常，这些共病可加速T2DM的疾病进展并导致更差的预后，显著增加患者的心血管事件发生率及死亡风险。在一项针对T2DM患者的2期临床研究中，HTD1801达到了主要终点（显著降低HbA1c）。根据最新诊断标准，该受试人群中可能有相当比例的患者同时患有代谢相关脂肪性肝病（MASLD，又称MAFLD）。本次分析以基线控制衰减参数值>288 dB/m（对应5%肝脂肪含量）作为诊断MASLD的标准，进一步评估了HTD1801在合并患有MASLD的T2DM患者中的疗效。结果显示，HTD1801可剂量依赖性地改善T2DM合并MASLD患者的多个肝脏与心脏代谢指标。这些数据表明，HTD1801在血糖控制基础上，可广泛改善代谢与心血管风险因素，为患者带来综合获益。"Rimtoregtide（HTD4010）及DUR-928在急性肝衰竭小鼠中的保护作用比较"（摘要FRI-141，欧洲中部时间5月9日，8:30AM，墙报）摘要：本研究旨在：1）评估Rimtoregtide（HTD4010）在脂多糖（LPS）诱导的急性肝衰竭小鼠模型中的潜在保护作用；2）与处于后期开发阶段、用于治疗酒精相关性肝炎的DUR-928进行比较研究。在 LPS 诱导的急性肝衰竭小鼠模型中，与对照组相比，HTD4010 显著提高了小鼠存活率（＞2倍）。HTD4010的对小鼠保护作用显著优于DUR-928。本次分析表明，HTD4010在急性肝病（包括酒精肝炎及其他急性炎症相关疾病）中具有潜在临床获益。关于熊去氧胆小檗碱（HTD1801）熊去氧胆小檗碱（HTD1801）是一种靶向肠-肝系统的口服抗炎及代谢调节剂，正在开发用于治疗代谢及消化系统疾病。HTD1801作为熊去氧胆酸和小檗碱形成的离子盐，是一种具有独特双机制的新分子实体，通过激活AMPK及抑制NLRP3发挥其生物学活性。这两种关键机制与改善胰岛素抵抗、葡萄糖代谢、脂质代谢和肝脏炎症相关，为复杂代谢性疾病的治疗提供综合性解决方案。HTD1801目前正在针对多种适应症进行临床开发，其在针对2型糖尿病（T2DM）开展的两项临床3期试验均达成主要终点，HTD1801可具有临床意义地显著改善HbA1c。同时，两项试验均达成多个次要终点， 表明HTD1801可带来心血管代谢指标改善等综合获益。除T2DM以外，在临床2a期研究中HTD1801展示了针对代谢相关脂肪性肝炎（MASH）治疗的有效性，目前针对该适应症的全球多中心 2b期临床试验正在顺利推进，预计2025年公布试验结果。关于Rimtoregtide（HTD4010）Rimtoregtide（HTD4010）是一款针对酒精性肝炎（AH）等急性炎症适应症开发的临床阶段的候选药物。HTD4010是一种Reg3α蛋白衍生肽，具有免疫调节、抗炎及抗细胞凋亡作用。临床前研究发现，HTD4010在急性胰腺炎和急性肝衰竭的动物模型中表现出良好的保护作用。此外，在已完成的1期临床试验中，HTD4010在健康受试者中展现出良好的安全性。AH由长期大量饮酒或短期内饮酒剧增所致，其主要特征为严重的肝脏炎症，进而可能导致肝衰竭甚至死亡。目前尚无获批治疗AH的药物，仅有极少数候选药物处于临床开发阶段，现有的临床治疗方案仍以症状管理为主，包括戒酒、消除炎症及补充营养等。关于君圣泰医药君圣泰医药（股票代码：2511.HK）是一家全球一体化的新型生物技术公司，专注代谢性疾病领域的重大未满足临床需求。以"标本兼治、深求治愈"这一DeepCure理念为目标，立足源头创新，开发First-in-Class的原创新药，以期为全球患者提供基于中国智慧的，安全、有效、综合获益的解决方案。基于自主知识产权，公司已构建丰富产品管线，在全球推进多项中、后期临床试验，开发代谢相关脂肪性肝炎（MASH）、2型糖尿病（T2DM）、严重高甘油三酯血症（SHTG）和原发性硬化性胆管炎（PSC）等适应症。作为同类首创的多靶点新分子实体，熊去氧胆小檗碱（HTD1801）被美国FDA授予2项"快速通道资格认定"、1项"孤儿药资格认定"，并获得国家"十三五-重大新药创制"科技重大专项支持。 Copyright 2025 亚太商讯 via SeaPRwire.com.